Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Miquelianin (quercetin 3-O-glucuronide) is a naturally occurring flavonoid glucuronide and a major metabolite of quercetin. It is found in several medicinal plants, including *Filipendula ulmaria* (meadowsweet), *Hypericum perforatum* (St. John's wort), and *Nelumbo nucifera* (lotus). Unlike many other quercetin conjugates, miquelianin is capable of crossing the blood-brain barrier, where it exerts neuroprotective, anti-inflammatory, and antioxidant effects. Research has focused on its potential to counteract neuroinflammation and impaired proteostasis, which are key drivers of Parkinson's disease and other neurodegenerative conditions. It also demonstrates geroprotective properties by modulating aging-associated mechanisms, potentially through the activation of SIRT1 and the inhibition of pro-inflammatory signaling pathways such as NF-kappaB.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on miquelianin.